Adial Pharmaceuticals to Present at Healthcare Conference

Got story updates? Submit your updates here. ›

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for addiction and related disorders, announced that CEO Cary Claiborne will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. The presentation will be webcast live and available for replay on the company's website.

Why it matters

Adial's lead investigational drug, AD04, is being developed to treat Alcohol Use Disorder (AUD) in heavy drinking patients. The company recently completed its ONWARD pivotal Phase 3 clinical trial, which showed promising results in reducing drinking with no major safety concerns. Presenting at the high-profile Oppenheimer conference will allow Adial to showcase its progress and potential treatments for addiction.

The details

Adial's presentation is scheduled for Wednesday, February 25, 2026 at 2:40 p.m. Eastern Time. In addition to the live webcast, the presentation will be available for replay on the company's investor relations website. Management will also be hosting one-on-one meetings with approved investors throughout the two-day conference.

• Adial's presentation is scheduled for February 25, 2026 at 2:40 p.m. Eastern Time.
• The Oppenheimer 36th Annual Healthcare Life Sciences Conference will be held virtually on February 25 - 26, 2026.

What’s next

The company's presentation at the Oppenheimer conference will provide an opportunity for Adial to showcase its progress and potential treatments for addiction disorders to the healthcare investment community.